Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Health Canada has approved ENFLONSIA® (clesrovimab) for the prevention of respiratory syncytial virus (RSV) ...

As several European countries are currently detecting respiratory syncytial virus (RSV) infections, ECDC issues rapid scientific advice for policymakers and public health authorities on ways to ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according to a study published online July 22 in Pediatrics.

Respiratory infections are the leading causes of hospitalizations, ED visits and mortality in children in the United States ...

July 17 (UPI) --The Food and Drug Administration announced Monday it has approved a drug by which newborns and infants can be protected against respiratory syncytial virus for an entire season with a ...

Please provide your email address to receive an email when new articles are posted on . Minimally invasive surfactant therapy did not lower mortality among preterm infants with respiratory distress ...

Objective: The aim of the study was to measure pulmonary mechanics in infants with respiratory distress syndrome before extubation and to correlate pulmonary function values with successful extubation ...

Infants born full term to mothers who were infected with COVID-19 during pregnancy had three times the risk of having respiratory distress compared with unexposed infants, even though they themselves ...

Prenatal exposure to air pollution increases the risk of severe respiratory distress in newborn babies, according to new research. The risk increases with exposure specifically to fine particulate ...

Consumption of cannabis (marijuana) or derivatives during pregnancy can cause respiratory problems for the baby, such as impaired control of breathing and diminished sensitivity to carbon dioxide, ...